OpenBilldrug price receipt

NADAC week of 2026-10-14

DASATINIB 100 MG TABLET

For 30 tablets

Pharmacies pay

$793.70 filed

30 × $26.45683 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23, 2026-09-30 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$8,968.25 filed

30 × $298.94158 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

11.3× estimated

Medicare paid 11.3× what pharmacies pay.

Part D averages every strength and form sold under “Dasatinib” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23, 2026-09-30 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$917.76 estimated

$793.70 + $119.06 (15%) + $5.00 fee per fill = $917.76

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23, 2026-09-30 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

DASATINIB 100 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as dasatinib.

FDA gives its dosage form as “tablet, film coated” and “tablet” and its route as oral.

FDA lists 10 labelers (the companies named on the label) for its NDCs, among them Teva Pharmaceuticals, Inc., Dr.Reddys Laboratories Inc and Aurobindo Pharma Limited.

FDA’s Established Pharmacologic Class for it is Kinase Inhibitor.

The NADAC file of 2026-10-14 prices it under 10 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $793.70 for 30 tablets (30 × $26.45683 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; those prices took effect between 2026-09-23 and 2026-09-30. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 6, the CMS Covered Outpatient Drug Product File S/I/N drug category was not applied when grouping drugs for the calculation.

The 10 labelers

LabelerNDCsPharmacies pay per unit
Apotex Corp.1$26.45683 per EA filed
Aurobindo Pharma Limited1$26.45683 per EA filed
Biocon Pharma Inc.1$26.45683 per EA filed
BluePoint Laboratories1$26.45683 per EA filed
Dr.Reddys Laboratories Inc1$26.45683 per EA filed
Lupin Pharmaceuticals, Inc.1$26.45683 per EA filed
NorthStar RxLLC1$26.45683 per EA filed
Prasco Laboratories1$26.45683 per EA filed
Teva Pharmaceuticals, Inc.1$26.45683 per EA filed
Zydus Pharmaceuticals USA Inc.1$26.45683 per EA filed

When these prices took effect

All 10 NDCs, with labeler and price
  • 00480-5104-56 · Teva Pharmaceuticals, Inc. · $26.45683 per EA · eff. 2026-09-23 filed
  • 43598-0603-30 · Dr.Reddys Laboratories Inc · $26.45683 per EA · eff. 2026-09-23 filed
  • 59651-0546-30 · Aurobindo Pharma Limited · $26.45683 per EA · eff. 2026-09-23 filed
  • 60505-3631-03 · Apotex Corp. · $26.45683 per EA · eff. 2026-09-23 filed
  • 66993-0237-30 · Prasco Laboratories · $26.45683 per EA · eff. 2026-09-23 filed
  • 68001-0664-04 · BluePoint Laboratories · $26.45683 per EA · eff. 2026-09-23 filed
  • 70377-0087-11 · Biocon Pharma Inc. · $26.45683 per EA · eff. 2026-09-23 filed
  • 70710-1745-03 · Zydus Pharmaceuticals USA Inc. · $26.45683 per EA · eff. 2026-09-23 filed
  • 70748-0212-06 · Lupin Pharmaceuticals, Inc. · $26.45683 per EA · eff. 2026-09-23 filed
  • 72603-0926-01 · NorthStar RxLLC · $26.45683 per EA · eff. 2026-09-30 filed

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name dasatinib with DASATINIB 100 MG TABLET.

ProductPharmacies pay per unitMedicare per unit
DASATINIB 100 MG TABLET this page
generic · tablet, film coated / tablet
$26.45683 per EA filed
eff. 2026-09-23 to 2026-09-30
$298.94158 per EA filed
Part D 2024 average
SPRYCEL 100 MG TABLET
brand · tablet
$591.1812 per EA filed
eff. 2026-05-20
$438.00015 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-05-20, 2026-09-23, 2026-09-30 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 10 NDCs’ NADAC prices is $26.45683 per EA filed.

Of the 20 other products in FDA’s Kinase Inhibitor class priced per EA, 4 have a higher middle NADAC price and 16 a lower one. The one in the middle is NINTEDANIB ESYLATE 150 MG CAP, at $13.45627 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $8,968.25 for 30 tablets, at an average of $298.94158 per EA in 2024 (2024-01-01 to 2024-12-31) for “Dasatinib”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 5,485 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for DASATINIB 100 MG TABLET labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Dasatinib / Dasatinib: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on generic name.